Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Imara appoints Stephen Migausky as general counsel » 07:24
05/04/20
05/04
07:24
05/04/20
07:24
IMRA

Imara

$16.90 /

-0.22 (-1.29%)

, ARQL

ArQule

$0.00 /

+ (+0.00%)

Imara (IMRA) announced…

Imara (IMRA) announced the appointment of Stephen Migausky as SVP, legal and general counsel. In this new role, Migausky will lead the Company's legal organization, including corporate governance and compliance functions. Prior to joining Imara, Migausky served as general counsel at ArQule (ARQL).

ShowHide Related Items >><<
IMRA Imara
$16.90 /

-0.22 (-1.29%)

04/07/20 Citi
Imara initiated with a Buy at Citi
04/06/20
Fly Intel: Top five analyst initiations
04/06/20 Morgan Stanley
Imara initiated with an Overweight at Morgan Stanley
04/06/20 SVB Leerink
IMARA initiated with an Outperform at SVB Leerink
ARQL ArQule
$0.00 /

+ (+0.00%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
Over a quarter ago
Hot Stocks
Replimune Group appoints Dieter Weinand as chairman of the board » 07:22
04/02/20
04/02
07:22
04/02/20
07:22
REPL

Replimune Group

$9.77 /

-0.085 (-0.86%)

, SNY

Sanofi

$42.75 /

-0.84 (-1.93%)

, ARQL

ArQule

$0.00 /

+ (+0.00%)

Replimune (REPL)…

Replimune (REPL) announced the appointment of Dieter Weinand as Chairman of the Board of Directors and the new appointment of Paolo Pucci to the Board of Directors, effective immediately. Mr. Weinand succeeds Philip Astley-Sparke who in January transitioned from part time Executive Chairman to full time CEO. Dieter Weinand was formally the EVP of Primary Care and a member of the Executive Committee at Sanofi (SNY) since November 1, 2018. Paolo Pucci most recently served as the CEO of ArQule (ARQL), a biopharmaceutical oncology company engaged in the research and development of targeted therapeutics.

ShowHide Related Items >><<
REPL Replimune Group
$9.77 /

-0.085 (-0.86%)

03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
08/06/19 Wedbush
Replimune Group, Sallie Mae removed from Best Ideas List at Wedbush
SNY Sanofi
$42.75 /

-0.84 (-1.93%)

03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
03/17/20 Barclays
Sanofi upgraded to Equal Weight from Underweight at Barclays
03/11/20 Oppenheimer
Regeneron price target raised to $525 from $450 at Oppenheimer
03/10/20 Goldman Sachs
Sanofi upgraded to Buy from Neutral at Goldman Sachs
ARQL ArQule
$0.00 /

+ (+0.00%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
Options
One option delisting on January 17th » 08:30
01/17/20
01/17
08:30
01/17/20
08:30
ARQL

ArQule

$19.99 /

+ (+0.00%)

Option delistings…

Option delistings effective January 17th include ArQule Inc (ARQL).

ShowHide Related Items >><<
ARQL ArQule
$19.99 /

+ (+0.00%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
Options
Largest borrow rate increases among liquid names » 08:45
01/16/20
01/16
08:45
01/16/20
08:45
TRIL

Trillium Therapeutics

$2.48 /

-0.17 (-6.42%)

, AMC

AMC Entertainment

$7.12 /

+0.26 (+3.79%)

, SDC

SmileDirectClub

$13.72 /

+2 (+17.06%)

, SA

Seabridge Gold

$13.48 /

+0.42 (+3.22%)

, VSTM

Verastem

$2.04 /

+0.11 (+5.70%)

, AM

Antero Midstream

$7.59 /

+0.18 (+2.43%)

, NUGT

Direxion Gold Miners Bull

$32.51 /

+1.63 (+5.28%)

, GDS

GDS Holdings

$52.57 /

+0.99 (+1.92%)

, ARQL

ArQule

$19.99 /

+0.01 (+0.05%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Trillium Therapeutics (TRIL) 66.45% +1.76, AMC Entertainment (AMC) 46.71% +0.92, SmileDirectClub (SDC) 19.48% +0.52, Seabridge Gold (SA) 1.98% +0.24, Verastem (VSTM) 38.03% +0.19, Antero Midstream (AM) 27.95% +0.18, Direxion Daily Gold Miners Bull 3X Shares (NUGT) 1.39% +0.17, GDS Holdings (ADS) (GDS) 0.42% +0.13, iShares MSCI Europe (EUFN) 0.98% +0.10, and ArQule (ARQL) 0.81% +0.08.

ShowHide Related Items >><<
TRIL Trillium Therapeutics
$2.48 /

-0.17 (-6.42%)

08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
03/12/19 H.C. Wainwright
Trillium Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
AMC AMC Entertainment
$7.12 /

+0.26 (+3.79%)

12/18/19
Fly Intel: Top five analyst downgrades
12/18/19 BofA
BofA/Merrill downgrades AMC Entertainment to Underperform with $7 target
12/18/19 BofA
AMC Entertainment downgraded to Underperform from Neutral at BofA/Merrill
11/22/19 B. Riley FBR
B. Riley FBR downgrades Cinemark and Marcus, cuts exhibitor targets
SDC SmileDirectClub
$13.72 /

+2 (+17.06%)

01/15/20 Jefferies
SmileDirect traditional channel entry makes competitive 'noise,' says Jefferies
01/14/20 Stifel
SmileDirectClub wholesale entrance offers 'incremental' sales, says Stifel
01/09/20 Wolfe Research
SmileDirectClub initiated with an Underperform at Wolfe Research
01/06/20 Craig-Hallum
SmileDirectClub initiated with a Buy at Craig-Hallum
SA Seabridge Gold
$13.48 /

+0.42 (+3.22%)

04/30/19 B. Riley FBR
Seabridge Gold initiated with a Buy at B. Riley FBR
VSTM Verastem
$2.04 /

+0.11 (+5.70%)

06/20/19 JonesTrading
JonesTrading downgrades Verastem as CEO marks third major management exit
06/20/19 JonesTrading
Verastem downgraded to Hold from Buy at JonesTrading
06/20/19 BTIG
Verastem downgraded to Neutral from Buy at BTIG
05/14/19 Roth Capital
Verastem price target lowered to $4 from $14 at Roth Capital
AM Antero Midstream
$7.59 /

+0.18 (+2.43%)

12/09/19 Ladenburg
Antero Midstream price target lowered to $8 from $10 at Ladenburg
11/06/19 Wells Fargo
Antero Midstream downgraded to Market Perform from Outperform at Wells Fargo
11/06/19 Wells Fargo
Antero Midstream downgraded to Market Perform from Outperform at Wells Fargo
10/03/19 JPMorgan
Antero Midstream reinstated with a Neutral rating at JPMorgan
NUGT Direxion Gold Miners Bull
$32.51 /

+1.63 (+5.28%)

GDS GDS Holdings
$52.57 /

+0.99 (+1.92%)

01/14/20
Fly Intel: Top five analyst initiations
01/14/20 Macquarie
GDS Holdings initiated with an Outperform at Macquarie
12/13/19 SunTrust
GDS Holdings price target raised to $55 from $51 at SunTrust
11/18/19 RBC Capital
GDS Holdings price target raised to $62 from $58 at RBC Capital
ARQL ArQule
$19.99 /

+0.01 (+0.05%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
  • 14
    Jan
Options
ArQule put volume heavy and directionally bearish » 09:55
01/10/20
01/10
09:55
01/10/20
09:55
ARQL

ArQule

$20.01 /

-0.005 (-0.02%)

Bearish flow noted in…

Bearish flow noted in ArQule with 2,040 puts trading, or 7x expected. Most active are Jan-22 20 puts and Jan-20 20 calls, with total volume in those strikes near 2,100 contracts. The Put/Call Ratio is 19.43, while ATM IV is up over 1 point on the day. Earnings are expected on March 5th.

ShowHide Related Items >><<
ARQL ArQule
$20.01 /

-0.005 (-0.02%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
Hot Stocks
Merck commences tender offer to acquire ArQule » 06:47
12/17/19
12/17
06:47
12/17/19
06:47
MRK

Merck

$89.29 /

+0.11 (+0.12%)

, ARQL

ArQule

$20.13 /

+0.06 (+0.30%)

Merck (MRK) is…

Merck (MRK) is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of ArQule (ARQL). On December 9, Merck announced its intent to acquire ArQule. Upon the successful closing of the tender offer, stockholders of ArQule will receive $20 in cash for each share of ArQule common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, ArQule will become a wholly-owned subsidiary of Merck. Merck will file with the U.S. SEC a tender offer statement on Schedule TO, which provides the terms of the tender offer. Additionally, ArQule will file with the SEC a solicitation/recommendation statement on Schedule 14D-9 that includes the recommendation of the ArQule board of directors that their stockholders accept the tender offer and tender their shares. The tender offer will expire at one minute past 11:59 pm Eastern Time on January 15, 2020, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC. The closing of the tender offer is subject to customary terms and conditions, including the tender of a number of shares which, together with shares then owned by Merck, represents a majority of the outstanding shares of common stock of ArQule, and the expiration or the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close early in the first quarter of 2020.

ShowHide Related Items >><<
MRK Merck
$89.29 /

+0.11 (+0.12%)

12/12/19 Stifel
Stifel says TherapeuticsMD's Annovera 'insulated' against generic NuvaRing
12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
ARQL ArQule
$20.13 /

+0.06 (+0.30%)

12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
Conference/Events
Cantor pharma/biotech analysts to hold an analyst/industry conference call » 12:25
12/16/19
12/16
12:25
12/16/19
12:25
AZN

AstraZeneca

$49.29 /

+0.93 (+1.92%)

, CTLT

Catalent

$53.26 /

+1 (+1.91%)

, ARQL

ArQule

$20.23 /

+0.16 (+0.80%)

, TGTX

TG Therapeutics

$9.98 /

-0.1 (-0.99%)

, LLY

Eli Lilly

$122.70 /

+1.16 (+0.95%)

Large Cap & Specialty…

Large Cap & Specialty Pharmaceuticals Analyst Chen and Biotech Analysts Young & Kumar, along with Key Opinion Leader Dr. Nam H. Dang, Professor of Medicine--Hematology/Oncology at the University of Florida, discuss takeaways from the recently-held 61st ASH Annual Meeting for BTK Inhibitors on an Analyst/Industry conference call to be held on December 16 at 1 pm.

ShowHide Related Items >><<
AZN AstraZeneca
$49.29 /

+0.93 (+1.92%)

12/16/19 Stifel
Stifel 'taking profits' on Amarin following FDA approval, downgrades to Hold
12/12/19 H.C. Wainwright
Zymeworks may have work-around to AEs of competing drug, says H.C. Wainwright
12/12/19 Deutsche Bank
Genmab downgraded to Hold from Buy at Deutsche Bank
12/02/19 Cowen
AstraZeneca price target raised to $55 from $48 at Cowen
CTLT Catalent
$53.26 /

+1 (+1.91%)

10/17/19 Stephens
Catalent resumed with an Overweight at Stephens
08/28/19
Fly Intel: Top five analyst downgrades
08/28/19 Baird
Catalent price target raised to $60 from $50 at Baird
08/28/19
Catalent downgraded to Sector Weight on valuation at KeyBanc
ARQL ArQule
$20.23 /

+0.16 (+0.80%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
TGTX TG Therapeutics
$9.98 /

-0.1 (-0.99%)

12/09/19 B. Riley FBR
TG Therapeutics price target raised to $17 from $12 at B. Riley FBR
11/27/19 B. Riley FBR
TG Therapeutics resumed with a Buy at B. Riley FBR
04/12/19 H.C. Wainwright
TG granted orphan status for three lymphoma indications, says H.C. Wainwright
03/29/19 Cantor Fitzgerald
Cantor starts TG Therapeutics with Overweight rating, $17 price target
LLY Eli Lilly
$122.70 /

+1.16 (+0.95%)

12/16/19 Piper Sandler
DexCom pact with Eli Lilly an 'incremental positive,' says Piper Jaffray
12/16/19 Cowen
Eli Lilly below consensus estimates raised to above consensus at Cowen
11/06/19 SVB Leerink
ArQule data for ARQ 531 'continue to look strong,' says SVB Leerink
10/16/19 BofA
Eli Lilly reinstated with a Buy at BofA/Merrill
Conference/Events
Cantor pharma/biotech analysts to hold an analyst/industry conference call » 04:55
12/16/19
12/16
04:55
12/16/19
04:55
AZN

AstraZeneca

$48.36 /

+0.43 (+0.90%)

, CTLT

Catalent

$52.26 /

+0.05 (+0.10%)

, ARQL

ArQule

$20.07 /

+0.08 (+0.40%)

, TGTX

TG Therapeutics

$10.08 /

+0.68 (+7.23%)

, LLY

Eli Lilly

$121.54 /

-0.15 (-0.12%)

Large Cap & Specialty…

Large Cap & Specialty Pharmaceuticals Analyst Chen and Biotech Analysts Young & Kumar, along with Key Opinion Leader Dr. Nam H. Dang, Professor of Medicine--Hematology/Oncology at the University of Florida, discuss takeaways from the recently-held 61st ASH Annual Meeting for BTK Inhibitors on an Analyst/Industry conference call to be held on December 16 at 1 pm.

ShowHide Related Items >><<
AZN AstraZeneca
$48.36 /

+0.43 (+0.90%)

12/12/19 H.C. Wainwright
Zymeworks may have work-around to AEs of competing drug, says H.C. Wainwright
12/12/19 Deutsche Bank
Genmab downgraded to Hold from Buy at Deutsche Bank
12/02/19 Cowen
AstraZeneca price target raised to $55 from $48 at Cowen
11/22/19
Fly Intel: Top five analyst initiations
CTLT Catalent
$52.26 /

+0.05 (+0.10%)

10/17/19 Stephens
Catalent resumed with an Overweight at Stephens
08/28/19
Fly Intel: Top five analyst downgrades
08/28/19 Baird
Catalent price target raised to $60 from $50 at Baird
08/28/19
Catalent downgraded to Sector Weight on valuation at KeyBanc
ARQL ArQule
$20.07 /

+0.08 (+0.40%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
TGTX TG Therapeutics
$10.08 /

+0.68 (+7.23%)

12/09/19 B. Riley FBR
TG Therapeutics price target raised to $17 from $12 at B. Riley FBR
11/27/19 B. Riley FBR
TG Therapeutics resumed with a Buy at B. Riley FBR
04/12/19 H.C. Wainwright
TG granted orphan status for three lymphoma indications, says H.C. Wainwright
03/29/19 Cantor Fitzgerald
Cantor starts TG Therapeutics with Overweight rating, $17 price target
LLY Eli Lilly
$121.54 /

-0.15 (-0.12%)

11/06/19 SVB Leerink
ArQule data for ARQ 531 'continue to look strong,' says SVB Leerink
10/16/19 BofA
Eli Lilly reinstated with a Buy at BofA/Merrill
09/25/19 Piper Sandler
AbbVie survey supports above-consensus estimates, says Piper Jaffray
09/09/19 Piper Sandler
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Conference/Events
Cantor pharma/biotech analysts to hold an analyst/industry conference call » 09:35
12/13/19
12/13
09:35
12/13/19
09:35
AZN

AstraZeneca

$47.93 /

-0.26 (-0.54%)

, CTLT

Catalent

$52.21 /

+0.02 (+0.04%)

, ARQL

ArQule

$19.99 /

-0.24 (-1.19%)

, TGTX

TG Therapeutics

$9.40 /

+0.46 (+5.15%)

, LLY

Eli Lilly

$121.69 /

+0.83 (+0.69%)

Large Cap & Specialty…

Large Cap & Specialty Pharmaceuticals Analyst Chen and Biotech Analysts Young & Kumar, along with Key Opinion Leader Dr. Nam H. Dang, Professor of Medicine--Hematology/Oncology at the University of Florida, discuss takeaways from the recently-held 61st ASH Annual Meeting for BTK Inhibitors on an Analyst/Industry conference call to be held on December 16 at 1 pm.

ShowHide Related Items >><<
AZN AstraZeneca
$47.93 /

-0.26 (-0.54%)

12/12/19 H.C. Wainwright
Zymeworks may have work-around to AEs of competing drug, says H.C. Wainwright
12/12/19 Deutsche Bank
Genmab downgraded to Hold from Buy at Deutsche Bank
12/02/19 Cowen
AstraZeneca price target raised to $55 from $48 at Cowen
11/22/19
Fly Intel: Top five analyst initiations
CTLT Catalent
$52.21 /

+0.02 (+0.04%)

10/17/19 Stephens
Catalent resumed with an Overweight at Stephens
08/28/19
Fly Intel: Top five analyst downgrades
08/28/19 Baird
Catalent price target raised to $60 from $50 at Baird
08/28/19
Catalent downgraded to Sector Weight on valuation at KeyBanc
ARQL ArQule
$19.99 /

-0.24 (-1.19%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital
TGTX TG Therapeutics
$9.40 /

+0.46 (+5.15%)

12/09/19 B. Riley FBR
TG Therapeutics price target raised to $17 from $12 at B. Riley FBR
11/27/19 B. Riley FBR
TG Therapeutics resumed with a Buy at B. Riley FBR
04/12/19 H.C. Wainwright
TG granted orphan status for three lymphoma indications, says H.C. Wainwright
03/29/19 Cantor Fitzgerald
Cantor starts TG Therapeutics with Overweight rating, $17 price target
LLY Eli Lilly
$121.69 /

+0.83 (+0.69%)

11/06/19 SVB Leerink
ArQule data for ARQ 531 'continue to look strong,' says SVB Leerink
10/16/19 BofA
Eli Lilly reinstated with a Buy at BofA/Merrill
09/25/19 Piper Sandler
AbbVie survey supports above-consensus estimates, says Piper Jaffray
09/09/19 Piper Sandler
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Options
ArQule call buyer realizes 69% same-day gains » 08:00
12/12/19
12/12
08:00
12/12/19
08:00
ARQL

ArQule

$20.23 /

+0.28 (+1.40%)

Notable profits for the…

Notable profits for the buyer who lifted the $0.40 offer for 3,612 ArQule (ARQL) Jan-20 20 calls yesterday at 11:27ET when underlying shares were trading at $20.07. Shares closed at $20.20, and the calls at $0.68 for a mark-to-market profit of 69%, or $99K, on the $144K outlay.

ShowHide Related Items >><<
ARQL ArQule
$20.23 /

+0.28 (+1.40%)

12/10/19 Roth Capital
ArQule downgraded to Neutral from Buy at Roth Capital
12/10/19 Cantor Fitzgerald
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
12/10/19 H.C. Wainwright
ArQule downgraded to Neutral from Buy at H.C. Wainwright
12/10/19 RBC Capital
ArQule downgraded to Sector Perform from Outperform at RBC Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.